Reduced striatal acetylcholine efflux in the R6/2 mouse model of Huntington's disease: An examination of the role of altered inhibitory and excitatory mechanisms

Experimental Neurology

Volumn 232, Issue 2, 2011, Pages 119-125

  Farrar, Andrew M ^a   Callahan, Joshua W ^a   Abercrombie, Elizabeth D ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

Basal ganglia; Cholinergic; Microdialysis; Neurodegeneration; Striatum; Transgenic

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 4 AMINOBUTYRIC ACID A RECEPTOR; ACETYLCHOLINE; BICUCULLINE METHIODIDE; DOPAMINE; DOPAMINE 1 RECEPTOR;

ACETYLCHOLINE BRAIN LEVEL; ACETYLCHOLINE RELEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLINERGIC NERVE CELL; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; EXTRACELLULAR SPACE; FUNCTIONAL STATUS; HUNTINGTON CHOREA; INTERNEURON; MALE; MICRODIALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; ROTAROD TEST;

2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; ACETYLCHOLINE; ANIMALS; BICUCULLINE; CHOLINERGIC NEURONS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGONISTS; EXCITATORY POSTSYNAPTIC POTENTIALS; GABA-A RECEPTOR ANTAGONISTS; HUMANS; HUNTINGTON DISEASE; INHIBITORY POSTSYNAPTIC POTENTIALS; INTERNEURONS; MICE; MICE, TRANSGENIC; MOTOR SKILLS; NERVE DEGENERATION; NERVE TISSUE PROTEINS; NEURAL INHIBITION; NUCLEAR PROTEINS; SYNAPTIC TRANSMISSION;

EID: 80054976927     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2011.08.010     Document Type: Article

References (59)

1. Abercrombie E.D., DeBoer P. Substantia nigra D1 receptors and stimulation of striatal cholinergic interneurons by dopamine: a proposed circuit mechanism. J. Neurosci. 1997, 17:8498-8505.
2. Acquas E., Wilson C., Fibiger H.C. Nonstriatal dopamine D1 receptors regulate striatal acetylcholine release in vivo. J. Pharmacol. Exp. Ther. 1997, 281:360-368.
3. Bonsi P., Cuomo D., Martella G., Madeo G., Schirinzi T., Puglisi F., Ponterio G., Pisani A. Centrality of striatal cholinergic transmission in Basal Ganglia function. Front. Neuroanat. 2011, 5:6.
4. Brooks S.P., Betteridge H., Trueman R.C., Jones L., Dunnett S.B. Selective extra-dimensional set shifting deficit in a knock-in mouse model of Huntington's disease. Brain Res. Bull. 2006, 69:452-457.
5. Brooks S.P., Janghra N., Higgs G.V., Bayram-Weston Z., Heuer A., Jones L., Dunnett S.B. Selective cognitive impairment in the YAC128 Huntington's disease mouse. Brain Res. Bull. 2011, doi:10.1016/j.brainresbull.2011.05.010. Epub ahead of print.
6. Brown H.D., Baker P.M., Ragozzino M.E. The parafascicular thalamic nucleus concomitantly influences behavioral flexibility and dorsomedial striatal acetylcholine output in rats. J. Neurosci. 2010, 30:14390-14398.
7. Calabresi P., Centonze D., Gubellini P., Bernardi G. Activation of M1-like muscarinic receptors is required for the induction of corticostriatal LTP. Neuropharmacology 1999, 38:323-326.
8. Calabresi P., Centonze D., Gubellini P., Pisani A., Bernardi G. Acetylcholine-mediated modulation of striatal function. Trends Neurosci. 2000, 23:120-126.
9. Callahan J.W., Abercrombie E.D. In vivo dopamine efflux is decreased in striatum of both fragment (R6/2) and full-length (YAC128) transgenic mouse models of Huntington's disease. Front. Syst. Neurosci. 2011, 5:61. 10.3389/fnsys.2011.00061.
10. Cepeda C., Wu N., André V.M., Cummings D.M., Levine M.S. The corticostriatal pathway in Huntington's disease. Prog. Neurobiol. 2007, 81:253-271.
11. Cha J.H., Kosinski C.M., Kerner J.A., Alsdorf S.A., Mangiarini L., Davies S.W., Penney J.B., Bates G.P., Young A.B. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:6480-6485.
12. Ciamei A., Morton A.J. Progressive imbalance in the interaction between spatial and procedural memory systems in the R6/2 mouse model of Huntington's disease. Neurobiol. Learn. Mem. 2009, 92:417-428.
13. Cobb W.S., Abercrombie E.D. Distinct roles for nigral GABA and glutamate receptors in the regulation of dendritic dopamine release under normal conditions and in response to systemic haloperidol. J. Neurosci. 2002, 22:1407-1413.
14. Consolo S., Wu C.F., Fusi R. D-1 receptor-linked mechanism modulates cholinergic neurotransmission in rat striatum. J. Pharmacol. Exp. Ther. 1987, 242:300-305.
15. Damsma G., Tham C.S., Robertson G.S., Fibiger H.C. Dopamine D1 receptor stimulation increases striatal acetylcholine release in the rat. Eur. J. Pharmacol. 1990, 186:335-338.
16. DeBoer P., Abercrombie E.D. Physiological release of striatal acetylcholine in vivo: modulation by D1 and D2 dopamine receptor subtypes. J. Pharmacol. Exp. Ther. 1996, 277:775-783.
17. DeBoer P., Heeringa M.J., Abercrombie E.D. Spontaneous release of acetylcholine in striatum is preferentially regulated by inhibitory dopamine D2 receptors. Eur. J. Pharmacol. 1996, 317:257-262.
18. Deng Y.P., Albin R.L., Penney J.B., Young A.B., Anderson K.D., Reiner A. Differential loss of striatal projection systems in Huntington's disease: a quantitative immunohistochemical study. J. Chem. Neuroanat. 2004, 27:143-164.
19. Di Filippo M., Tozzi A., Picconi B., Ghiglieri V., Calabresi P. Plastic abnormalities in experimental Huntington's disease. Curr. Opin. Pharmacol. 2007, 7:106-111.
20. Ding J.B., Guzman J.N., Peterson J.D., Goldberg J.A., Surmeier D.J. Thalamic gating of corticostriatal signaling by cholinergic interneurons. Neuron 2010, 67:294-307.
21. Fage D., Scatton B. Opposing effects of D-1 and D-2 receptor antagonists on acetylcholine levels in the rat striatum. Eur. J. Pharmacol. 1986, 129:359-362.
22. Ferrante R.J., Kowall N.W., Beal M.F., Richardson E.P., Bird E.D., Martin J.B. Selective sparing of a class of striatal neurons in Huntington's disease. Science 1985, 230:561-563.
23. Ferrante R.J., Kowall N.W., Beal M.F., Martin J.B., Bird E.D., Richardson E.P. Morphologic and histochemical characteristics of a spared subset of striatal neurons in Huntington's disease. J. Neuropathol. Exp. Neurol. 1987, 46:12-27.
24. Freeman W., Morton A.J. Regional and progressive change in brain expression of complexin II in a mouse transgenic for the Huntington's disease mutation. Brain Res. Bull. 2004, 63:45-55.
25. Glass M., Dragunow M., Faull R.L. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 2000, 97:505-519.
26. Glass M., van Dellen A., Blakemore C., Hannan A.J., Faull R.L.M. Delayed onset of Huntington's disease in mice in an enriched environment correlates with delayed loss of cannabinoid CB1 receptors. Neuroscience 2004, 123:207-212.
27. Gourfinkel-An I., Parain K., Hartmann A., Mangiarini L., Brice A., Bates G., Hirsch E.C. Changes in GAD67 mRNA expression evidenced by in situ hybridization in the brain of R6/2 transgenic mice. J. Neurochem. 2003, 86:1369-1378.
28. Heinsen H., Rüb U., Gangnus D., Jungkunz G., Bauer M., Ulmar G., Bethke B., Schüler M., Böcker F., Eisenmenger W., Götz M., Strik M. Nerve cell loss in the thalamic centromedian-parafascicular complex in patients with Huntington's disease. Acta Neuropathol. 1996, 91:161-168.
29. Imperato A., Obinu M.C., Casu M.A., Mascia M.S., Dazzi L., Gessa G.L. Evidence that neuroleptics increase striatal acetylcholine release through stimulation of dopamine D1 receptors. J. Pharmacol. Exp. Ther. 1993, 266:557-562.
30. Johnson M.A., Rajan V., Miller C.E., Wightman R.M. Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease. J. Neurochem. 2006, 97:737-746.
31. Kliem M.A., Maidment N.T., Ackerson L.C., Chen S., Smith Y., Wichmann T. Activation of nigral and pallidal dopamine D1-like receptors modulates basal ganglia outflow in monkeys. J. Neurophysiol. 2007, 98:1489-1500.
32. Lapper S.R., Bolam J.P. Input from the frontal cortex and the parafascicular nucleus to cholinergic interneurons in the dorsal striatum of the rat. Neuroscience 1992, 51:533-545.
33. Lawrence A.D., Sahakian B.J., Hodges J.R., Rosser A.E., Lange K.W., Robbins T.W. Executive and mnemonic functions in early Huntington's disease. Brain 1996, 119(Pt 5):1633-1645.
34. Lawrence A.D., Hodges J.R., Rosser A.E., Kershaw A., ffrench-Constant C., Rubinsztein D.C., Robbins T.W., Sahakian B.J. Evidence for specific cognitive deficits in preclinical Huntington's disease. Brain 1998, 121(Pt 7):1329-1341.
35. Lawrence A.D., Sahakian B.J., Rogers R.D., Hodge J.R., Robbins T.W. Discrimination, reversal, and shift learning in Huntington's disease: mechanisms of impaired response selection. Neuropsychologia 1999, 37:1359-1374.
36. Lehmann J., Langer S.Z. The striatal cholinergic interneuron: synaptic target of dopaminergic terminals. Neuroscience 1983, 10:1105-1120.
37. Levine M.S., Cepeda C., Hickey M.A., Fleming S.M., Chesselet M.F. Genetic mouse models of Huntington's and Parkinson's diseases: illuminating but imperfect. Trends Neurosci. 2004, 27:691-697.
38. Lione L.A., Carter R.J., Hunt M.J., Bates G.P., Morton A.J., Dunnett S.B. Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation. J. Neurosci. 1999, 19:10428-10437.
39. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87:492-506.
40. Miller B.R., Bezprozvanny I. Corticostriatal circuit dysfunction in Huntington's disease: intersection of glutamate, dopamine and calcium. Future Neurol. 2010, 5:735-756.
41. Morton A.J., Edwardson J.M. Progressive depletion of complexin II in a transgenic mouse model of Huntington's disease. J. Neurochem. 2001, 76:166-172.
42. Morton A.J., Hunt M.J., Hodges A.K., Lewis P.D., Redfern A.J., Dunnett S.B., Jones L. A combination drug therapy improves cognition and reverses gene expression changes in a mouse model of Huntington's disease. Eur. J. Neurosci. 2005, 21:855-870.
43. Ortiz A.N., Kurth B.J., Osterhaus G.L., Johnson M.A. Impaired dopamine release and uptake in R6/1 Huntington's disease model mice. Neurosci. Lett. 2011, 492:11-14.
44. Petersén A., Puschban Z., Lotharius J., NicNiocaill B., Wiekop P., O'Connor W.T., Brundin P. Evidence for dysfunction of the nigrostriatal pathway in the R6/1 line of transgenic Huntington's disease mice. Neurobiol. Dis. 2002, 11:134-146.
45. Picconi B., Passino E., Sgobio C., Bonsi P., Barone I., Ghiglieri V., Pisani A., Bernardi G., Ammassari-Teule M., Calabresi P. Plastic and behavioral abnormalities in experimental Huntington's disease: a crucial role for cholinergic interneurons. Neurobiol. Dis. 2006, 22:143-152.
46. Pisani A., Bernardi G., Ding J., Surmeier D.J. Re-emergence of striatal cholinergic interneurons in movement disorders. Trends Neurosci. 2007, 30:545-553.
47. Ragozzino M.E., Mohler E.G., Prior M., Palencia C.A., Rozman S. Acetylcholine activity in selective striatal regions supports behavioral flexibility. Neurobiol. Learn. Mem. 2009, 91:13-21.
48. Reiner A., Albin R.L., Anderson K.D., D'Amato C.J., Penney J.B., Young A.B. Differential loss of striatal projection neurons in Huntington disease. Proc. Natl. Acad. Sci. U.S.A. 1988, 85:5733-5737.
49. Sidibé M., Paré J., Smith Y. Nigral and pallidal inputs to functionally segregated thalamostriatal neurons in the centromedian/parafascicular intralaminar nuclear complex in monkey. J. Comp. Neurol. 2002, 447:286-299.
50. Smith R., Chung H., Rundquist S., Maat-Schieman M.L.C., Colgan L., Englund E., Liu Y., Roos R.A.C., Faull R.L.M., Brundin P., Li J. Cholinergic neuronal defect without cell loss in Huntington's disease. Hum. Mol. Genet. 2006, 15:3119-3131.
51. Stoof J.C., Drukarch B., DeBoer P., Westerink B.H., Groenewegen H.J. Regulation of the activity of striatal cholinergic neurons by dopamine. Neuroscience 1992, 47:755-770.
52. Sullivan M.A., Huanmian C., Morikawa H. Recurrent inhibitory network among striatal cholinergic interneurons. J. Neurosci. 2008, 28:8682-8690.
53. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72:971-983. The Huntington's Disease Collaborative Research Group.
54. Timmerman W., Westerink B.H. Extracellular gamma-aminobutyric acid in the substantia nigra reticulata measured by microdialysis in awake rats: effects of various stimulants. Neurosci. Lett. 1995, 197:21-24.
55. Trevitt T., Carlson B., Correa M., Keene A., Morales M., Salamone J.D. Interactions between dopamine D1 receptors and gamma-aminobutyric acid mechanisms in substantia nigra pars reticulata of the rat: neurochemical and behavioral studies. Psychopharmacology (Berl.) 2002, 159:229-237.
56. Van Raamsdonk J.M., Pearson J., Slow E.J., Hossain S.M., Leavitt B.R., Hayden M.R. Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease. J. Neurosci. 2005, 25:4169-4180.
57. Vetter J.M., Jehle T., Heinemeyer J., Franz P., Behrens P.F., Jackisch R., Landwehrmeyer G.B., Feuerstein T.J. Mice transgenic for exon 1 of Huntington's disease: properties of cholinergic and dopaminergic pre-synaptic function in the striatum. J. Neurochem. 2003, 85:1054-1063.
58. Wang Z., Kai L., Day M., Ronesi J., Yin H.H., Ding J., Tkatch T., Lovinger D.M., Surmeier D.J. Dopaminergic control of corticostriatal long-term synaptic depression in medium spiny neurons is mediated by cholinergic interneurons. Neuron 2006, 50:443-452.
59. Zackheim J., Abercrombie E.D. Thalamic regulation of striatal acetylcholine efflux is both direct and indirect and qualitatively altered in the dopamine-depleted striatum. Neuroscience 2005, 131:423-436.